Topics:

What’s around the corner? Take a peek at 4 technologies in progress aimed at improving diabetes management.

NATIONAL HARBOR, MD—Experts at SIIM 2015 predict the end of PACS is near.

(CCR2015) Nearly 100 new molecules are in development as RA treatments. This summary of a recent presentation by the ever-eloquent Ed Keystone MD gives a brief rundown of their mechanisms, progress, and potential.

The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?

Are you letting meaningless details squander your mental currency in rheumatology practice? The author points out how to recapture energy stolen by mere paperwork that should be used on your real job: Patient care.

A 2-year study found a threefold increased risk of cardiovascular disease in older patients with major depression.

Nonsmokers who inhaled vapor from electronic cigarettes had diminished cough reflex after a single exposure, a new study found.

Several new studies feature developments in remyelination in MS. Oligodendrocyte precursor cells may be a promising target for MS treatments, and microRNA expression are perhaps an attractive MS biomarker.

Pages

Subscribe to ConsultantLive RSS

By clicking Accept, you agree to become a member of the UBM Medica Community.